Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.

Stopped early

Conditions studied: RELAPSING REMITTING MULTIPLE SCLEROSIS

In brief

The purpose of this research is to characterize the effect of teriflunomide on the activation of B-cells, as well as its capacity to modify B-cell cytokine secretion. The in-vitro identified effects of teriflunomide on the expression of B-cell activation markers, costimulatory and antigen presenting molecules, as well as on cytokine secretion, will then be confirmed in a cohort of Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with this medication.

Key facts

Study ID

NCT02833714

Run by

University of North Carolina, Chapel Hill

People needed

26

Starts

2016-01-01

Expected to finish

2016-12-21

Last updated by the study team

2017-09-15

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• confirmed diagnosis of RRMS according to McDonald's diagnostic criteria,
• age 18-55,
• an extended disability status score (EDSS) of 1.5-5.5.

You may not qualify if…

• Previous treatment with DMT.

Where it is running

• University of North Carolina — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.